CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Entasis Therapeutics Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Entasis Therapeutics Holdings Inc
35 Gatehouse Drive
Phone: (781) 810-0120p:781 810-0120 WALTHAM, MA  02451  United States Fax: (302) 655-5049f:302 655-5049

This company was Merged or Acquired on 7/11/2022.
This company ceased filing statements with the SEC on 7/21/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
Entasis Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/202212/31/2021YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer & Director ManoussosPerros
Chief Financial Officer & Chief Business Officer MichaelGutch
Chief Medical Officer RobinIsaacs
11 additional Officers and Directors records available in full report.

Business Names
Business Name
Entasis Therapeutics (Ireland) Limited
Entasis Therapeutics Inc.
Entasis Therapeutics Limited
Entasis Therapeutics Security Corporation
ETTX

General Information
Number of Employees: 51 (As of 12/31/2021)
Outstanding Shares: 47,851,779 (As of 4/22/2022)
Shareholders: 10
Stock Exchange: NASD
Federal Tax Id: 824592913
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 2, 2024